We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Search Results

Showing 1-20 of 3,376 results
  1. Rozanolixizumab in generalized myasthenia gravis: a profile of its use

    Rozanolixizumab (rozanolixizumab-noli; RYSTIGGO ® ), a humanized IgG4 monoclonal antibody with a high affinity and specificity for human neonatal Fc...

    Sheridan M. Hoy in Drugs & Therapy Perspectives
    Article 20 July 2024
  2. Treat atopic dermatitis during pregnancy with safe and effective therapies

    The complex hormonal and immunological changes that occur during pregnancy can lead to the development of specific skin conditions, of which atopic...

    Amy Zhuang-Yan in Drugs & Therapy Perspectives
    Article 20 July 2024
  3. The changing landscape of medicare part D coverage: effects of the Inflation Reduction Act (IRA) in dermatology

    Medicare Part D holds an important role in facilitating prescription drug coverage for older adults in the United States seeking dermatologic...

    Kennedy Sparling, Sami Jelousi, Daniel C. Butler in Drugs & Therapy Perspectives
    Article 18 July 2024
  4. Glucocorticoid-induced osteoporosis—from molecular mechanism to clinical practice

    Glucocorticoids (GCs) are essential and effective medications commonly prescribed to patients with autoimmune disorders and inflammatory diseases....

    Chueh Hsuan Hsu, Chueh Lin Hsu, ... Bogna Grygiel-Górniak in Drugs & Therapy Perspectives
    Article Open access 18 July 2024
  5. Management of orofacial pain starts with careful differentiation of odontogenic and non-odontogenic pain

    The diagnosis and management of orofacial pain can be challenging, especially when pain of non-odontogenic origin mimics dental pain or is localised...

    Esther S. Kim, Simon Fung in Drugs & Therapy Perspectives
    Article 13 July 2024
  6. Personalise treatment for rosacea by selecting from a range of options for individual features

    Rosacea is a chronic, inflammatory condition of facial skin. Treatment of rosacea should be based on its presenting features i.e. inflammatory...

    Article 11 July 2024
  7. Take an individualized approach when managing women of reproductive age with uterine fibroids

    Uterine fibroids are the most common gynaecological tumour in women of reproductive age and can cause heavy menstrual bleeding, anaemia, pelvic pain,...

    Sheridan M. Hoy in Drugs & Therapy Perspectives
    Article 09 July 2024
  8. Medication errors in older patients: a pharmacovigilance perspective

    Introduction

    Drug regulatory agencies are particularly interested in pharmacovigilance data relating to medication errors (MEs) involving a...

    Marie-Laure Laroche, Michel Guillaumin, ... Marie-Blanche Valnet-Rabier in Drugs & Therapy Perspectives
    Article 09 July 2024
  9. Long-term topical corticosteroid treatment for atopic dermatitis: an in-depth analysis of safety, efficacy, withdrawal, and patient experiences

    Atopic dermatitis, often referred to as eczema, is classified as a chronic inflammatory skin disorder with increasing prevalence. Topical...

    Alyssa Ingurgio in Drugs & Therapy Perspectives
    Article 09 July 2024
  10. Corticosteroids are still first-line therapies for bullous pemphigoid, with biologics finding use in difficult-to-treat disease

    Bullous pemphigoid is an autoantibody-mediated subepidermal blistering disorder which develops predominately in patients of advanced age....

    Article 05 July 2024
  11. Adis summary of research: Matching‑adjusted indirect comparisons of diroximel fumarate, ponesimod, and teriflunomide for relapsing multiple sclerosis

    Several oral disease-modifying therapies (DMTs) have been approved for the treatment of relapsing multiple sclerosis (MS), including diroximel...

    Hannah A. Blair in Drugs & Therapy Perspectives
    Article 01 July 2024
  12. Zuranolone in postpartum depression: a profile of its use in the USA

    Zuranolone (ZURZUVAE ® ), an orally bioavailable neuroactive steroid and a selective, positive, allosteric modulator of both synaptic and extrasynaptic...

    Hannah A. Blair in Drugs & Therapy Perspectives
    Article 19 June 2024
  13. Add or switch to systemics and biologics where topical paediatric hidradenitis suppurativa therapy fails

    Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin condition that typically develops in adults but can rarely affect...

    Caroline Fenton, Connie Kang in Drugs & Therapy Perspectives
    Article 18 June 2024
  14. Current and emerging immunobiologic therapies for atopic dermatitis

    Atopic dermatitis (AD) is a chronically relapsing inflammatory skin disease with a multifactorial etiology that affects up to 20% of children and up...

    Hemali Shah, Francelia J. Eckembrecher, ... Keyvan Nouri in Drugs & Therapy Perspectives
    Article Open access 13 June 2024
  15. Fezolinetant in the treatment of vasomotor symptoms associated with menopause: a profile of its use

    Fezolinetant (VEOZAH ; Veoza ), a first-in-class neurokinin 3 receptor (NK3R) antagonist, represents a promising novel non-hormonal treatment option...

    Hannah A. Blair in Drugs & Therapy Perspectives
    Article 27 May 2024
  16. Dietary supplements may boost memory, but more evidence is required

    Over the counter dietary supplements are a massive and growing market; however, there are few regulations or safeguards/protections for ensuring...

    Article 15 May 2024
  17. Aim to alleviate alopecia areata with newly available agents

    The autoimmune, chronic hair loss known as alopecia areata (AA) is traditionally treated with anti-inflammatory, immunosuppressant agents,...

    Caroline Fenton, Connie Kang in Drugs & Therapy Perspectives
    Article 01 May 2024
  18. Adis summary of research: A 10-year observational study of the use, acceptability and effectiveness of long-acting paliperidone palmitate: implications for clinical decision making

    Atypical long-acting injectable antipsychotics, such as paliperidone palmitate, play an important role in the management of psychotic disorders. They...

    Yahiya Y. Syed in Drugs & Therapy Perspectives
    Article 01 May 2024
  19. Adis summary of research: Safety, tolerability and pharmacokinetics of aripiprazole 2-monthly formulation in patients with schizophrenia or bipolar I disorder

    The once-monthly long-acting injectable (LAI) formulation of aripiprazole, an atypical antipsychotic that stabilizes the dopamine-serotonin system,...

    Hannah A. Blair in Drugs & Therapy Perspectives
    Article 01 May 2024
Did you find what you were looking for? Share feedback.